AbbVie, a pharmaceutical company, focuses on immunology, oncology, neuroscience, and aesthetics. Despite a significant decrease in third-quarter earnings, the company raised its full-year guidance. The stock’s valuation is a concern for long-term investors. AbbVie faces challenges with patent expirations but benefits from strong brands like Botox. Despite a tough quarter, AbbVie raised its full-year earnings guidance and increased its dividend. The stock remains near all-time highs, but traditional valuation metrics indicate it may be expensive. Wall Street remains optimistic about AbbVie, offering an attractive dividend yield. Consider the stock’s contradictions before deciding to buy.

Read more at Nasdaq: Is AbbVie a Millionaire Maker?